Status:

COMPLETED

Effects of Atorvastatin Versus Pravastatin on Platelet Inhibition by Clopidogrel

Lead Sponsor:

Shenyang Northern Hospital

Conditions:

Ischemic Heart Disease

Acute Coronary Syndromes

Eligibility:

All Genders

18-85 years

Phase:

PHASE4

Brief Summary

Clopidogrel and statins are frequently coadministered in patients with ischemic heart diseases. Recent reports suggested that clopidogrel's effectiveness in inhibiting adenosine diphosphate (ADP)-indu...

Eligibility Criteria

Inclusion

  • Diagnosed with ACS.
  • Between ages of 18 Years and 85 years.
  • Presence of one or several stenosis in native coronary arteries requiring PCI.
  • Willing and able to sign informed consent.

Exclusion

  • A history of bleeding diathesis.
  • New York Heart Association functional class IV.
  • Prior PCI or coronary bypass grafting \< 3 months.
  • Contraindications to statins, clopidogrel and aspirin (White blood cells counts \< 4×109/L or platelet counts \<100 g/l; creatinine clearance \<25 ml/ min; active liver disease).
  • Use of glycoprotein IIb/IIIa inhibitors before PCI.
  • Use of statins before PCI.

Key Trial Info

Start Date :

February 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 1 2008

Estimated Enrollment :

1300 Patients enrolled

Trial Details

Trial ID

NCT00405717

Start Date

February 1 2006

End Date

May 1 2008

Last Update

November 7 2008

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Northern Hospital

Shenyang, Liaoning, China

Effects of Atorvastatin Versus Pravastatin on Platelet Inhibition by Clopidogrel | DecenTrialz